Vyleesi Young Adult (18 to 29) Dosing: Bremelanotide Guide for Premenopausal Women

Is there a different Vyleesi dose for women aged 18 to 29?

No. The label gives one dose for the whole approved population: 1.75 mg injected subcutaneously into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity [1]. The label's dosage section gives no age-based, weight-based or body-mass-index-based adjustment, and Vyleesi comes as a prefilled autoinjector that the patient self-injects, so nothing is measured or mixed [1].

The population that dose was studied in is premenopausal women with acquired, generalized HSDD: desire that used to be normal for the woman, is low regardless of the type of stimulation, situation or partner, and causes marked distress or interpersonal difficulty that is not explained by a medical or psychiatric condition, a relationship problem, or a medication or drug [1]. In the two phase 3 trials, participants ranged from 19 to 56 years old, with a mean age of 39, and the label does not report doses or results separately for women aged 18 to 29 [1].

The label also limits what the drug is for: it is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance [1].

How often women actually used it in the trials

Most patients in the phase 3 program used Vyleesi two to three times a month, and no more than once a week [1]. That sits well below the ceiling the label sets. The label says not to give more than one dose within 24 hours, and that more than 8 doses per month is not recommended [1]. Two reasons appear in the label for the monthly figure: only a few patients in the phase 3 program used more than 8 doses a month, and more frequent dosing raises the risk of focal hyperpigmentation and lengthens the time each month when blood pressure is increased [1].

The label also states that the duration of efficacy after each dose is unknown and that the optimal window for injecting has not been fully characterized; the label says patients may decide the best timing from how long they feel an effect on desire and from any reactions such as nausea [1].

What the 8-week checkpoint means

The label instruction is to stop Vyleesi after 8 weeks if there has been no improvement in symptoms [1]. In the two identical 24-week trials, 1,267 women were randomized. The safety population included 627 women who received Vyleesi and 620 who received placebo; 1,202 women were included in the efficacy analysis [1][2].

The measured benefit was modest and specific. On the Female Sexual Function Index desire domain, the label reports a change from baseline of 0.5 with Vyleesi versus 0.2 with placebo in study 1, and 0.6 versus 0.2 in study 2 [1]. The pooled analyses reported improvements over placebo of 0.30 (study 301), 0.42 (study 302) and 0.35 integrated points, all with P<0.001 [2]. Distress related to low desire fell by 0.37, 0.29 and 0.33 points respectively [2]. The number of satisfying sexual events did not differ significantly from placebo [2].

Dropouts matter when reading those numbers. In study 1, 40% of Vyleesi patients versus 13% of placebo patients stopped early; in study 2, 39% versus 25% [1]. The label also reports an exploratory analysis restricted to women who completed 24 weeks and improved from baseline [1]. Across the trials, 18% of Vyleesi patients discontinued because of adverse reactions versus 2% on placebo [1].

Side effects at the 1.75 mg dose

Nausea is the most common reaction. In the pooled phase 3 trials it was reported by 40.0% of women on Vyleesi versus 1.3% on placebo; 13% needed an anti-nausea medicine and 8% stopped the trials because of it [1]. Median onset was within one hour of the dose and it lasted about two hours; it was highest after the first dose (21% of patients) and fell to about 3% with later doses [1]. The label says nausea improved for most patients with the second dose, and says to consider discontinuing Vyleesi for persistent or severe nausea, or starting anti-emetic therapy for patients who are bothered but wish to continue [1].

In a phase 4 study of 228 healthy women, 8 mg of oral ondansetron taken 30 minutes before a 1.75 mg Vyleesi injection did not reduce the incidence of nausea compared with placebo, so the label does not recommend that pretreatment [1]. Ondansetron given after the injection or after nausea begins has not been formally studied [1].

Flushing (20.3% vs 0.3%), injection site reactions (13.2% vs 8.4%), headache (11.3% vs 1.9%) and vomiting (4.8% vs 0.2%) were the next most common. Serious adverse reactions were reported in 1.1% on Vyleesi versus 0.5% on placebo [1].

Blood pressure and heart rate

Vyleesi transiently raises blood pressure and lowers heart rate after each dose [1]. The label reports maximal increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with a heart rate reduction of up to 5 beats per minute; values usually return to baseline within 12 hours, and repeat daily dosing 24 hours apart for up to 16 days showed no additive effect [1]. Those are maximal figures, not averages. In an open-label ambulatory monitoring study of 127 premenopausal women dosed once daily for 8 days, the mean daytime increase was 1.9 mmHg systolic (95% CI 1.0 to 2.7) and 1.7 mmHg diastolic (95% CI 0.9 to 2.4), with a mean heart rate decrease of 0.5 beats per minute [1].

Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease, and it is not recommended for patients at high risk of cardiovascular disease [1]. The label says to consider cardiovascular risk and ensure blood pressure is well controlled before starting and periodically during treatment [1].

Focal hyperpigmentation

Bremelanotide is a melanocortin receptor agonist that, at therapeutic doses, binds MC1R and MC4R most relevantly; MC1R sits on pigment cells, and binding there increases pigmentation [1]. Darkening of the skin, gums or breasts, including the face, was reported by 1% of patients who used up to 8 doses a month in the placebo-controlled trials, and by no placebo patients [1]. The rate climbs steeply with daily dosing: in another study, 38% of patients developed focal hyperpigmentation after 8 daily doses, and a further 14% developed new pigmentary changes after 8 more consecutive days [1]. Patients with dark skin were more likely to develop it, resolution was not confirmed in all patients after stopping, and the label says to consider discontinuing Vyleesi if hyperpigmentation develops [1].

Pregnancy, contraception and the label update

The label says to stop Vyleesi if pregnancy is suspected and to use effective contraception while taking it [1]. In animal studies, daily subcutaneous bremelanotide given to pregnant dogs at exposures at least 16 times the maximum recommended human dose by AUC produced fetal harm, and developmental effects appeared in mouse offspring at 125 times the human dose or more [1]. Human data are thin: 7 pregnancies were reported in trials of more than 1,057 patients treated for up to 12 months, with no major congenital anomalies, one miscarriage, five full-term live births and one unknown outcome [1].

FDA approved a labeling supplement for Vyleesi (S-005) on October 22, 2026 that updates Section 8, Use in Specific Populations, and the patient information; that new text was not yet in the DailyMed version of the label as of October 28, 2026 [3][1].

Interactions worth knowing

The two interactions the label singles out are oral naltrexone and indomethacin. Vyleesi may significantly decrease the systemic exposure of orally administered naltrexone, and the label says to avoid combining them when the naltrexone product is intended to treat alcohol or opioid addiction, because naltrexone treatment failure has severe consequences [1]. More broadly, Vyleesi may slow gastric emptying and reduce the rate and extent of absorption of oral medicines: the label says to avoid it with oral drugs that depend on threshold concentrations for efficacy, naming antibiotics as an example, and says patients should consider discontinuing Vyleesi if an oral medicine's effect is delayed when a quick onset is desired, with indomethacin for pain relief as its example [1]. In clinical pharmacology studies, only naltrexone and indomethacin were meaningfully affected [1].

The label does not restrict alcohol. In a crossover study of 24 healthy volunteers, alcohol at 0.6 g/kg did not change the pharmacokinetic profile of bremelanotide, and flushing and headache rates with the combination were similar to the higher of the two single-agent rates [1]. That study used a 20 mg intranasal dose, which produces about 2.5 times the peak concentration of Vyleesi [1].

Vyleesi versus PT-141 sold online

Vyleesi is the FDA-approved bremelanotide product, approved June 21, 2019 under NDA 210557 and now held by Cosette Pharmaceuticals [1][4]. PT-141 sold as a compounded or research-use peptide is not Vyleesi and is not an FDA-approved drug, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [5][1].